ArticleAmerican journal of translational research2012
Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.
Article in American journal of translational research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 237 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
237 citing papers in PubMed.
- Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities.Human vaccines & immunotherapeutics · 2026Article
- TRIM24 in Human Cancers: A Dual-Function Oncoprotein, Regulatory Mechanisms, and Emerging Therapeutic Strategies.International journal of cancer · 2026Review
- The pivotal role of macrophages in tumorigenesis and pioneering cancer immunotherapy across pre-clinical and clinical frontiers.Journal of cancer research and clinical oncology · 2026Review
- Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment.Nature cancer · 2026Review
- Article
- Modeling immunotherapies in live 3D human cancer tissue bioreactors.Theranostics · 2026Article
- T-cell exhaustion in tumor immunology: mechanisms, heterogeneity, and therapeutic strategies.Frontiers in immunology · 2026Review
- Article
- Novel Computational Analysis Identifies Cytotoxic Lymphocyte-to-Monocyte Balance in Tumors as a Predictor of Recurrence-Free Survival in Colorectal Carcinoma.Annals of surgical oncology · 2025Article
- Immunotherapy and the Tumor Microenvironment in Brain Metastases from Non-Small Cell Lung Cancer: Challenges and Future Directions.Current oncology (Toronto, Ont.) · 2025Review
- Liposome-mediated macrophage reprogramming: emerging strategies for chronic disease therapy.Frontiers in immunology · 2025Review
- Lung cancer immunotherapy in 2025: where we stand and what comes next?Frontiers in immunology · 2025Review
- Recent Advancements in Immunotherapy for the Treatment of Metastatic Breast Cancer.Cancer treatment and research · 2025Review
- CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancer.Frontiers in pharmacology · 2025Article
- The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.Frontiers in oncology · 2025Article
- Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor Sizes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The trends and hotspots of immunotherapy for metastatic colorectal cancer from 2013 to 2022: A bibliometric and visual analysis.Human vaccines & immunotherapeutics · 2024Article
- The expression of CCL17 and potential prognostic value on tumor immunity in thyroid carcinoma based on bioinformatics analysis.Scientific reports · 2024Article
- Targeting Cancer: Microenvironment and Immunotherapy Innovations.International journal of molecular sciences · 2024Review
- Immune Response Modulation by HPV16 Oncoproteins in Lung Cancer: Insights from Clinical and In Vitro Investigations.Viruses · 2024Article
177 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Macrophages are the dominant leukocyte population found in the tumor microenvironment. Accumulating evidence suggests that these tumor-associated macrophages (TAMs) actively promote all aspects of tumor initiation, growth, and development. However, TAMs are not a single uniform population; instead, they are composed of multiple distinct pro- and anti-tumoral subpopulations with overlapping features depending on a variety of external factors. Defining and differentiating these subsets remains a challenging work-in-progress. These difficulties are apparent in prognostic studies in lung cancer that initially demonstrated conflicting evidence regarding the significance of TAMs but which have more recently clarified and confirmed the clinical importance of these subsets through improved phenotypic capabilities. Thus, these cells represent potential targets for cancer therapeutic initiatives through translational approaches. In this review, we summarize the current understanding of how the tumor microenvironment takes advantage of macrophage plasticity to mold an immunosuppressive population, the phenotypic heterogeneity of TAMs, and their link to prognosis in human lung cancer.
Indexed as
Identifiers
23145206PMC3493031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.